These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 33893295)
41. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. Gonçalves J; Santos CD; Fresco P; Fernandez-Llimos F Rev Port Cardiol; 2023 Apr; 42(4):373-383. PubMed ID: 36893838 [TBL] [Abstract][Full Text] [Related]
42. Two hits to the renin-angiotensin system may play a key role in severe COVID-19. Tseng YH; Yang RC; Lu TS Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292 [TBL] [Abstract][Full Text] [Related]
43. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis. Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423 [TBL] [Abstract][Full Text] [Related]
44. ACE2: from protection of liver disease to propagation of COVID-19. Warner FJ; Rajapaksha H; Shackel N; Herath CB Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956 [TBL] [Abstract][Full Text] [Related]
45. SARS-CoV-2 and hypertension. Ravichandran B; Grimm D; Krüger M; Kopp S; Infanger M; Wehland M Physiol Rep; 2021 Jun; 9(11):e14800. PubMed ID: 34121359 [TBL] [Abstract][Full Text] [Related]
46. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines. Li J; Wang P; Tracey KJ; Wang H Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793 [TBL] [Abstract][Full Text] [Related]
47. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
48. ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad? Wenzel UO; Kintscher U Am J Hypertens; 2021 Apr; 34(3):274-277. PubMed ID: 33151267 [No Abstract] [Full Text] [Related]
49. SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis. Delpino MV; Quarleri J Front Cell Infect Microbiol; 2020; 10():340. PubMed ID: 32596170 [No Abstract] [Full Text] [Related]
50. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637 [TBL] [Abstract][Full Text] [Related]
52. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019. Suh SH; Ma SK; Kim SW; Bae EH Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712 [TBL] [Abstract][Full Text] [Related]
53. Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2. Liu J; Lu F; Chen Y; Plow E; Qin J J Biol Chem; 2022 Mar; 298(3):101710. PubMed ID: 35150743 [TBL] [Abstract][Full Text] [Related]
54. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
55. Endocrine and metabolic aspects of COVID-19. Pawlikowski M; Winczyk K Endokrynol Pol; 2021; 72(3):256-260. PubMed ID: 34010445 [TBL] [Abstract][Full Text] [Related]
56. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise. Joseph S; Nair B; Nath LR Curr Mol Med; 2021; 21(10):888-913. PubMed ID: 33563197 [TBL] [Abstract][Full Text] [Related]
57. The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review. Naveed H; Elshafeey A; Al-Ali D; Janjua E; Nauman A; Kawas H; Kaul R; Saed Aldien A; Elshazly MB; Zakaria D J Clin Pharmacol; 2021 Aug; 61(8):987-1000. PubMed ID: 33635546 [TBL] [Abstract][Full Text] [Related]
58. Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes. Silva MG; Falcoff NL; Corradi GR; Alfie J; Seguel RF; Tabaj GC; Iglesias LI; Nuñez M; Guman GR; Gironacci MM Life Sci; 2022 Mar; 293():120324. PubMed ID: 35032553 [TBL] [Abstract][Full Text] [Related]
59. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407 [TBL] [Abstract][Full Text] [Related]